Status:

COMPLETED

Early On-therapy PET at First-line Treatment in Diffuse Large B-cell Lymphoma Stage IIB-IV

Lead Sponsor:

Copenhagen University Hospital at Herlev

Collaborating Sponsors:

Nordic Lymphoma Group

Conditions:

Diffuse Large-Cell Lymphoma

Eligibility:

All Genders

18+ years

Brief Summary

Early identification of refractory lymphoma patients provides a basis for stratification between responders to standard approaches and non-responders who may benefit from an early change to an alterna...

Detailed Description

Title: Evaluation of response to treatment using 18F-FDG positron emission tomography imaging (PET) in diffuse large B-cell lymphoma stage IIB-IV with special emphasize on the prognostic significance ...

Eligibility Criteria

Inclusion

  • Age ≥ 18 years.
  • Newly diagnosed consecutive patients with diffuse large B-cell lymphoma (DLBCL) according to the WHO classification.
  • Ann Arbor stage IIB-IV.
  • Written informed consent.

Exclusion

  • Previously treated with chemotherapy or irradiation.
  • Previous malignant diagnosis except basal cell carcinoma and cervical carcinoma in situ.
  • Pregnancy.
  • Lactation.
  • Diabetes mellitus.
  • Extreme adipositas.
  • Claustrophobia.
  • Active inflammatory disease or infection.

Key Trial Info

Start Date :

August 1 2005

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

January 1 2011

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT00286832

Start Date

August 1 2005

End Date

January 1 2011

Last Update

July 6 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Hematology, Odense University Hospital

Odense, Denmark, 5000